Previous 10 |
SOHM, Inc. ( OTCPK:SHMN ): Q1 Revenue of $0.18M More news on: SOHM, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
Chino Hills, CA, July 17, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer, release its first Qtr of 2018. YEAR END 2016 12 months ended Dec 2016 TOTAL REVENUE $124,261; GROSS PROFIT $94,006 YEAR END 2017 12 m...
Chino Hills, Jan. 19, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer, announces today that it has signed a binding Letter of Intent with a Canadian Institutional Investor for a sizable investment in SOHM. The proposed, non-t...
News, Short Squeeze, Breakout and More Instantly...
Sohm Inc Company Name:
SHMN Stock Symbol:
OTCMKTS Market:
2024-06-10 13:45:34 ET CAR T-cell therapy has seen significant growth and much promise, as it provides targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiatio...
CHINO HILLS, CA / ACCESSWIRE / June 10, 2024 / SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnology company that manufactures and markets generic drugs covering numerous treatment categories, announced that preliminary data from a 3 rd party user resulted in AB...
SOHM (OTC: SHMN) , a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize gen...